Jinwei Zhang
Medical School, College of Medicine and Health, University of Exeter, Hatherly Laboratories, Exeter, EX4 4PS, UK, Email- j.zhang5@exeter.ac.uk Phone: M: +44(0)7588671955 (UK) O: +44 (0)139272 3828 (UK); Skype: zhang-jinwei
Note: Photo must be less than 4 kilobytes and width* height is 85*119
Dr Jinwei Zhang is an Associated Professor at the University of Exeter Medical School, UK; Research Professor at Xiamen University China, Visiting Fellow at Yale School of Medicine US. His laboratory studies ion channels, transporters, and signalling pathways that associated with human diseases, for examples, stroke that regulated by WNK-SPAK/OSR1-KCC2/NKCC1, hypertension that regulated by WNK-SPAK/OSR1-NCC, and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules, CRISPR/Cas9 gene-editing technologies, and electrophysiology to aid discovery and validation of new potential drug targets. He is internationally recognized for his expertise in cellular chloride homeostasis and cell volume regulation and drug discovery. He has published more than 70 articles in journals including Nature Medicine, Cell Metabolism, Neuron, Nature Communications, EMBO molecular medicine, Science Signalling, Human Molecular Genetics etc. and has achieved more than 2420 citations, H-index=28.. He is an Associate Editor for the Frontiers in Pharmacology, and Frontiers in Physiology. He is currently a member of the editorial boards of 15 scientific journals, as well as a reviewer for more than 40 scientific journals.
His laboratory studies ion channels, transporters, and signalling pathways that associated with human diseases, for examples, stroke that regulated by WNK-SPAK/OSR1-KCC2/NKCC1, hypertension that regulated by WNK-SPAK/OSR1-NCC, and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules, CRISPR/Cas9 gene-editing technologies, and electrophysiology to aid discovery and validation of new potential drug targets.